OMEGA HEALTHCARE INVESTORS INCOHIEarnings & Financial Report
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
OHI Q4 2025 Key Financial Metrics
Revenue
$319.2M
Gross Profit
N/A
Operating Profit
$171.3M
Net Profit
$164.8M
Gross Margin
N/A
Operating Margin
53.7%
Net Margin
51.6%
YoY Growth
14.3%
EPS
$0.56
Financial Flow
OMEGA HEALTHCARE INVESTORS INC Q4 2025 Financial Summary
OMEGA HEALTHCARE INVESTORS INC reported revenue of $319.2M for Q4 2025, with a net profit of $164.8M (51.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $319.2M |
|---|---|
| Net Profit | $164.8M |
| Gross Margin | N/A |
| Operating Margin | 53.7% |
| Report Period | Q4 2025 |
OMEGA HEALTHCARE INVESTORS INC Annual Revenue by Year
OMEGA HEALTHCARE INVESTORS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.2B |
| 2024 | $1.1B |
| 2023 | $949.7M |
| 2022 | $878.2M |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $243.3M | $252.7M | $276.0M | $279.3M | $276.8M | $282.5M | $311.6M | $319.2M |
| YoY Growth | 11.5% | 1.0% | 14.0% | 16.7% | 13.8% | 11.8% | 12.9% | 14.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $9.01B | $8.85B | $9.57B | $9.90B | $9.71B | $10.55B | $10.60B | $10.05B |
| Liabilities | $5.31B | $4.95B | $5.17B | $5.17B | $4.77B | $5.36B | $5.35B | $4.61B |
| Equity | $3.51B | $3.71B | $4.21B | $4.54B | $4.74B | $4.99B | $5.04B | $5.18B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $151.5M | $184.1M | $184.9M | $229.0M | $182.0M | $239.3M | $226.7M | $230.6M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M